[an error occurred while processing this directive]
综述

终末期肾病透析患者肌少症的发病机制及诊治进展

  • 万利 ,
  • 王梅
展开
  • 102202  北京,1北京大学国际医院肾脏内科血液净化中心
    100044  北京,2北京大学人民医院肾内科

收稿日期: 2022-09-29

  修回日期: 2022-11-16

  网络出版日期: 2023-02-12

The pathogenesis and treatment of sarcopenia in end-stage renal disease patients on maintenance dialysis

  • WAN Li ,
  • WANG Mei
Expand
  • 1Blood Purification Center, Department of Nephrology, Peking University International Hospital, Beijing 102206, China; 2Department of Nephrology, Peking University People’s Hospital, Beijing 100044, China

Received date: 2022-09-29

  Revised date: 2022-11-16

  Online published: 2023-02-12

摘要

肌少症是以骨骼肌质量、力量以及功能降低为主要特征的退行性综合征。终末期肾病透析患者由于疾病本身、各种并发症、透析治疗及其带来的活动减少等,可加速肌肉消耗,增加肌少症的发生。透析患者合并肌少症的发生率高,死亡率高,需要早期预防、早期诊断和治疗。现就透析患者肌少症的发病机制及诊治进展进行综述。

本文引用格式

万利 , 王梅 . 终末期肾病透析患者肌少症的发病机制及诊治进展[J]. 中国血液净化, 2023 , 22(02) : 128 -132 . DOI: 10.3969/j.issn.1671-4091.2023.02.011

Abstract

Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass, strength and function. End-stage renal disease (ESRD) patients are at a higher risk of accelerated muscle wasting due to the renal diseases itself, various complications, dialysis treatment and reduced activity from dialysis treatment. The incidence of sarcopenia is higher in dialysis patients and the mortality will be increased in dialysis patients with sarcopenia, highlighting the great importance of early prevention, detection and treatment of muscle wasting. In this article, we summarize the pathogenesis, diagnosis and treatment of sarcopenia in ESRD patients on maintenance dialysis.

参考文献

[1]Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al.Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People[J].Age Ageing, 2010, 39(4):412-23
[2]Sabatino A, Regolisti G, Delsante M, et al.Noninvasive evaluation of muscle mass by ultrasonography of quadriceps femoris muscle in End-Stage Renal Disease patients on hemodialysis[J].Clin Nutr, 2019, 38(3):1232-9
[3]Chen LK, Liu LK, Woo J, et al.Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia[J].J Am Med Dir Assoc, 2014, 15(2):95-101
[4]Cruz-Jentoft AJ, Bahat G, Bauer J, et al.Sarcopenia: revised European consensus on definition and diagnosis[J].Age Ageing, 2019, 48(1):16-31
[5]Fielding RA, Vellas B, Evans WJ, et al.Sarcopenia: an undiagnosed condition in older adultsCurrent consensus definition: prevalence,etiology,and consequences. International working group on sarcopenia[J].J Am Med Dir Assoc, 2011, 12(4):249-56
[6]Studenski SA, Peters KW, Alley DE, et al.The FNIH sarcopenia project: rationale,study description,conference recommendations,and final estimates[J].J Gerontol A Biol Sci Med Sci, 2014, 69(5):547-58
[7]Chen LK, Woo J, Assantachai P, et al.Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment[J].J Am Med Dir Assoc, 2020, 21(3):300-7
[8]Shu X, Lin T, Wang H, et al.Diagnosis,prevalence,and mortality of sarcopenia in dialysis patients: a systematic review and meta-analysis[J].J Cachexia Sarcopenia Muscle, 2022, 13(1):145-58
[9]Lin YL, Liou HH, Wang CH, et al.Impact of sarcopenia and its diagnostic criteria on hospitalization and mortality in chronic hemodialysis patients: A 3-year longitudinal study[J].J Formos Med Assoc, 2020, 119(7):1219-29
[10]Sabatino A, Cuppari L, Stenvinkel P, et al.Sarcopenia in chronic kidney disease: what have we learned so far?[J].J Nephrol, 2021, 34(4):1347-72
[11]Wang XH, Mitch WE.Mechanisms of muscle wasting in chronic kidney disease[J].Nat Rev Nephrol, 2014, 10(9):504-16
[12]Mitch WE, Goldberg AL.Mechanisms of muscle wastingThe role of the ubiquitin-proteasome pathway[J].N Engl J Med, 1996, 335(25):1897-905
[13]Bataille S, Chauveau P, Fouque D, et al.Myostatin and muscle atrophy during chronic kidney disease[J].Nephrol Dial Transplant, 2021, 36(11):1986-93
[14]Du J, Wang X, Miereles C, et al.Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions[J].J Clin Invest, 2004, 113(1):115-23
[15]Sandri M.Autophagy in health and disease3. Involvement of autophagy in muscle atrophy[J].Am J Physiol Cell Physiol, 2010, 298(6):C1291-7
[16]Sandri M.Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome[J].Int J Biochem Cell Biol, 2013, 45(10):2121-9
[17]Gordon BS, Kelleher AR, Kimball SR.Regulation of muscle protein synthesis and the effects of catabolic states[J].Int J Biochem Cell Biol, 2013, 45(10):2147-57
[18]Schardong J, Marcolino MAZ, Plentz RDM.Muscle Atrophy in Chronic Kidney Disease[J].Adv Exp Med Biol, 2018, 1088:393-412.
[19]Cheng TC, Huang SH, Kao CL, et al.Muscle Wasting in Chronic Kidney Disease: Mechanism and Clinical Implications-A Narrative Review[J].Int J Mol Sci, 2022, 23(11):-
[20]Robinson KA, Baker LA, Graham-Brown MPM, et al.Skeletal muscle wasting in chronic kidney disease: the emerging role of microRNAs[J].Nephrol Dial Transplant, 2020, 35(9):1469-78
[21]Deger SM, Hung AM, Gamboa JL, et al.Systemic inflammation is associated with exaggerated skeletal muscle protein catabolism in maintenance hemodialysis patients[J].JCI Insight, 2017, 2(22):-
[22]Amitani M, Asakawa A, Amitani H, et al.Control of food intake and muscle wasting in cachexia[J].Int J Biochem Cell Biol, 2013, 45(10):2179-85
[23]Cobo G, Lindholm B, Stenvinkel P.Chronic inflammation in end-stage renal disease and dialysis[J].Nephrol Dial Transplant, 2018, 33(suppl_3):i-i
[24]Wang AY.Consequences of chronic inflammation in peritoneal dialysis[J].Semin Nephrol, 2011, 31(2):159-71
[25]Garagarza C, Valente A, Caetano C, et al.Dietary Intake,Body Composition,and Clinical Parameters: Associations Between the Level and Type of Physical Activity in Hemodialysis Patients[J].J Phys Act Health, 2021, 18(10):1223-30
[26]Gungor O, Ulu S, Hasbal NB, et al.Effects of hormonal changes on sarcopenia in chronic kidney disease: where are we now and what can we do?[J].J Cachexia Sarcopenia Muscle, 2021, 12(6):1380-92
[27]Gibson NR, Fereday A, Cox M, et al.Influences of dietary energy and protein on leucine kinetics during feeding in healthy adults[J].Am J Physiol, 1996, 270(2 Pt 1):E282-91
[28]Copur S, Sag AA, Afsar B, et al.Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer[J].Int Urol Nephrol, 2020, 52(12):2311-20
[29]Brüggemann AK, Mello CL, Dal Pont T, et al.Effects of Neuromuscular Electrical Stimulation During Hemodialysis on Peripheral Muscle Strength and Exercise Capacity: A Randomized Clinical Trial[J].Arch Phys Med Rehabil, 2017, 98(5):822-31
[30]Hewitt NA, O' Connor AA, O' Shaughnessy DV, et al.Effects of cholecalciferol on functional,biochemical,vascular,and quality of life outcomes in hemodialysis patients[J].Clin J Am Soc Nephrol, 2013, 8(7):1143-1149
[31]Muramatsu H, Kuramochi T, Katada H, et al.Novel myostatin-specific antibody enhances muscle strength in muscle disease models[J].Sci Rep, 2021, 11(1):2160-
[32]Lin YL, Chen SY, Lai YH, et al.Angiotensin II receptor blockade is associated with preserved muscle strength in chronic hemodialysis patients[J].BMC Nephrol, 2019, 20(1):54-
文章导航

/

[an error occurred while processing this directive]